Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial

Vipul Jairath, Silvio Danese, Geert D’Haens, Brian G. Feagan, Laurent Peyrin-Biroulet, Bruce E. Sands, Ingrid C. Gaemers, Matt Westfall, Allyson Terry, Kevin J. Roberts, Sara Barbat, Pamela Wedel, Jacqueline Benson, Carlos Sattler